PTH Analog Therapy in CKD G4-G5D: Current Evidence and Potential Role of Abaloparatide in Adynamic Bone Disease


Por: Gifre, L, Fusaro, M, Lloret, MJ, Massó, E, Peris, P, Nogués, X, Gelpi, R, Prior-Español, A, Ara, J, Cozzolino, M, Ureña-Torres, PA and Bover, J

Publicada: 24 dic 2025 Ahead of Print: 24 dic 2025
Resumen:
Osteoporosis and fragility fractures are among the most prevalent and clinically significant complications in patients with chronic kidney disease (CKD), particularly in stages G4-G5 and in those undergoing dialysis (G5D). These skeletal disorders are associated with markedly increased morbidity and mortality, including a 2- to 9-fold higher risk of hip fractures compared to the general population, prolonged hospitalization, functional decline, and excess postoperative mortality. Despite this substantial burden, CKD-associated osteoporosis remains underrecognized and undertreated. Limited inclusion of CKD patients in pivotal osteoporosis trials and the absence of high-evidence guidance in clinical guidelines have contributed to a persistent therapeutic gap. PTH analog agents such as teriparatide and abaloparatide have demonstrated robust efficacy in increasing bone mass and reducing fracture risk in the general population. However, their use in CKD remains limited. PTH analog are poorly prescribed in patients with CKD stage G3 and remain off-label for stages G4-G5D, despite the high prevalence of adynamic bone disease across all stages of CKD. Abaloparatide, a selective PTH1 receptor agonist, exerts potent anabolic effects with a lower incidence of hypercalcemia than teriparatide and may offer a favourable safety profile in carefully selected patients. Preliminary data suggest preservation of bone microarchitecture and potential benefits in low-turnover bone disease, although evidence in CKD is still limited. This narrative review examines current evidence on abaloparatide's potential role in CKD, emphasizing its mechanism of action, efficacy, safety, and relevance for patients with low bone turnover and high fracture risk.

Filiaciones:
:
 Univ Autonoma Barcelona, Hosp Germans Trias & Pujol, Res Inst Germans Trias & Pujol IGTP, Rheumatol Dept, C Canyet S-N, Badalona 08196, Spain

Fusaro, M:
 Univ Padua, Dept Med, I-35122 Padua, Italy

 Natl Res Council CNR, Inst Clin Physiol IFC, I-00185 Pisa, Italy

Lloret, MJ:
 Univ Autonoma Barcelona, Inst Recerca St Pau IR St Pau, Nephrol Dept, Fundacio Puigvert, Barcelona 08025, Spain

Massó, E:
 Univ Autonoma Barcelona, Univ Hosp Germans Trias & Pujol, Res Inst Germans Trias & Pujol IGTP, Nephrol Dept,RICORS 2040,REMAR IGTP Grp, Badalona 08196, Spain

Peris, P:
 Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed August Pi I Sunyer FRCB IDIBAPS, Rheumatol Dept,Fundacio Recerca Clin Barcelona, Barcelona 08036, Spain

Nogués, X:
 Univ Pompeu Fabra, Hosp Del Mar, CIBER Envejecimiento & Fragil Saludable, Internal Med Dept,Res Inst, Barcelona 08003, Spain

Gelpi, R:
 Univ Autonoma Barcelona, Univ Hosp Germans Trias & Pujol, Res Inst Germans Trias & Pujol IGTP, Nephrol Dept,RICORS 2040,REMAR IGTP Grp, Badalona 08196, Spain

:
 Univ Autonoma Barcelona, Hosp Germans Trias & Pujol, Res Inst Germans Trias & Pujol IGTP, Rheumatol Dept, C Canyet S-N, Badalona 08196, Spain

Ara, J:
 Univ Autonoma Barcelona, Univ Hosp Germans Trias & Pujol, Res Inst Germans Trias & Pujol IGTP, Nephrol Dept,RICORS 2040,REMAR IGTP Grp, Badalona 08196, Spain

Cozzolino, M:
 Univ Milan, Dept Hlth Sci, Renal Div, I-20122 Milan, Italy

Ureña-Torres, PA:
 AURA Nord St Ouen, Dept Nephrol & Dialysis, F-93400 St Ouen, France

 Univ Paris 05, Necker Hosp, Dept Renal Physiol, F-75015 Paris, France

:
 Univ Autonoma Barcelona, Univ Hosp Germans Trias & Pujol, Res Inst Germans Trias & Pujol IGTP, Nephrol Dept,RICORS 2040,REMAR IGTP Grp, Badalona 08196, Spain
ISSN: 20770383





Journal of Clinical Medicine
Editorial
MDPI, ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND, Suiza
Tipo de documento: Review
Volumen: 15 Número: 1
Páginas:
WOS Id: 001657406700001
ID de PubMed: 41517382
imagen Green Submitted, gold

MÉTRICAS